<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00824005</url>
  </required_header>
  <id_info>
    <org_study_id>580</org_study_id>
    <secondary_id>U01HL087318</secondary_id>
    <secondary_id>1 U01-HL-087318-01 (Project 3)</secondary_id>
    <nct_id>NCT00824005</nct_id>
  </id_info>
  <brief_title>Effectiveness of Stem Cell Treatment for Adults With Ischemic Cardiomyopathy (The FOCUS Study)</brief_title>
  <official_title>Randomized, Controlled, Phase II, Double-Blind Trial of Intramyocardial Injection of Autologous Bone Marrow Mononuclear Cells Under Electromechanical Guidance for Patients With Chronic Ischemic Heart Disease and Left Ventricular Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cardiovascular Cell Therapy Research Network (CCTRN)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coronary artery disease (CAD) is a common disorder that can lead to heart failure. Not all
      people with CAD are eligible for today's standard treatments. One new treatment approach uses
      stem cells—specialized cells capable of developing into other types of cells—to stimulate
      growth of new blood vessels for the heart. This study will determine the safety and
      effectiveness of withdrawing stem cells from someone's bone marrow and injecting those cells
      into the person's heart as a way of treating people with CAD and heart failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coronary artery disease (CAD), a disease in which blood vessels become clogged by a build-up
      of plaque, is the leading cause of heart failure, a condition in which the heart can no
      longer pump enough blood to the rest of the body. People with heart failure caused by CAD are
      said to have ischemic cardiomyopathy. Normal treatment for CAD involves coronary artery
      bypass grafting (in which a vein from another part of the body is grafted around an artery
      that has become blocked) or coronary angioplasty and stent placement (in which a blocked
      artery is opened and a small tube is placed to keep the artery open). However, some people
      with ischemic cardiomyopathy, such as those with substantial scar tissue on the heart wall or
      those with a particular heart structure, may not be eligible for these treatments. An
      alternative treatment being developed is therapeutic angiogenesis, which involves stimulating
      the growth of new blood vessels. Recent research has shown that withdrawing stem cells from
      bone marrow and implanting the cells into heart tissue may be an effective way to achieve
      therapeutic angiogenesis. This study will determine the safety and effectiveness of using
      stem cells to stimulate new blood vessel growth in the hearts of people with ischemic
      cardiomyopathy.

      Participation in this study, including follow-up visits and phone calls, will last 60 months.
      Participants will first undergo 3 to 4 days of screening procedures that will include a
      physical examination, multiple lab tests, and a battery of tests on heart health. Next,
      participants will be randomized to receive either active stem cell injections or placebo
      injections. The injections and related procedures will be performed in a hospital and last
      approximately 72 hours. During this time, participants in both groups will first undergo a
      bone marrow aspiration procedure. Participants receiving active stem cells will also undergo
      NOGA electromechanical cardiac mapping, which involves inserting a monitoring device through
      a catheter and into the heart. Injections of stem cells will then be made to 15 damaged sites
      on the heart through a special catheter. Participants receiving placebo injections will
      receive 15 injections of an inactive, saline-based solution. After the injection procedures,
      all participants will undergo two echocardiograms, an electrocardiogram, blood tests, and
      overnight monitoring in a telemetry unit.

      After the hospital stay, all participants will attend five study visits that will occur 1
      week and 1, 3, 6, and 12 months after the injection procedures. At all study visits,
      participants will undergo an electrocardiogram, lab tests, and a review of adverse health
      events. On all but the last study visit, participants will have cardiac markers assessed, and
      they will wear a 24-hour Holter monitor to track heart activity. At the last three visits,
      participants will also complete quality of life questionnaires. All participants will then
      receive four follow-up telephone calls that will occur 2, 3, 4, and 5 years after the
      injection procedures.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Maximal Oxygen Consumption (VO2max)</measure>
    <time_frame>Measured at Baseline and Month 6</time_frame>
    <description>The VO2(max) is assessed using the Naughton treadmill protocol.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Left Ventricular End Systolic Volume (LVESV)as Assessed Via Echo</measure>
    <time_frame>Measured at Baseline and Month 6</time_frame>
    <description>Echocardiographic measurements were performed by an echocardiographic core laboratory. LVESVs were calculated by the modified biplane Simpson method, using myocardial contrast to enhance endocardial definition. To account for patient body surface area, LVESV indices are reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Reversible Defect Size</measure>
    <time_frame>Measured at Baseline and Month 6</time_frame>
    <description>Adenosine myocardial perfusion (SPECT) tests were collected at baseline and 6 months to identify change in ischemic (reversible) defects. SPECT imaging was performed at rest and after adenosine infusion over 4 minutes. To enhance the detection of viability on resting images, sublingual nitroglycerin was administered 15 minutes before injecting technetium Tc 99m sestamibi for the resting image.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Regional Wall Motion by MRI (in Eligible Patients)</measure>
    <time_frame>Measured at Baseline and Month 6</time_frame>
    <description>Regional wall motion as measured by cardiac MRI (in patients who are not contraindicated)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regional Blood Flow Improvement by MRI (in Eligible Patients)</measure>
    <time_frame>Measured at Baseline and Month 6</time_frame>
    <description>Regional blood flow improvement as measured by cardiac MRI (in patients who are not contraindicated)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regional Wall Motion by Echocardiography</measure>
    <time_frame>Measured at Baseline and Month 6</time_frame>
    <description>Movement of the left ventricular wall measured in mm from baseline to six months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Improvement in CCS Classification (Angina Pectoris)</measure>
    <time_frame>Measured at Baseline and Month 6</time_frame>
    <description>Clinical improvement in Canadian Cardiovascular Society (CCS) functional classification of angina pectoris. The CCS scale ranges from Class I (best)&quot;able to conduct ordinary daily activity without causing angina&quot; to Class IV (worst) &quot;Inability to perform any physical activity without discomfort; anginal symptoms may be present at rest.&quot; Patients receive a rating of 1-4 for their anginal symptoms. Results reflect the mean change in the total score over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Improvement in NYHA Classification</measure>
    <time_frame>Measured at Baseline and Month 6</time_frame>
    <description>Clinical improvement in New York Heart Association (NYHA) classification. The NYHA scale ranges from 1 (best)&quot;Mild- no limitation of physical activity due to heart failure&quot; to 4 (worst) &quot;Severe-Unable to carry out any physical activity without discomfort due to heart failure&quot;. Patients receive a rating of 1-4 for their heart failure symptoms. Results reflect the mean change in the total score over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Decrease in Anti-anginal Medication</measure>
    <time_frame>Measured at Baseline and Month 6</time_frame>
    <description>Number of participants with a decrease in anti-anginal medication (nitrates needed weekly)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise Time and Level</measure>
    <time_frame>Measured at Baseline and Month 6</time_frame>
    <description>Exercise time and level as assessed via six minute walk test. (change in number of feet walked)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum BNP Levels in Patients With CHF</measure>
    <time_frame>Measured at Baseline and Month 6</time_frame>
    <description>Serum b-type natriuretic peptide (BNP) levels in patients with congestive heart failure (CHF). A minority number of patients had pro-BNP collected versus regular BNP; these numbers are reported in the analysis population description.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV Diastolic Dimension</measure>
    <time_frame>Measured at Baseline and Month 6</time_frame>
    <description>Left ventricular (LV) diastolic dimension as assessed by contrast echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of a Major Adverse Cardiac Event</measure>
    <time_frame>Measured at Baseline and Month 6</time_frame>
    <description>Incidence of major adverse cardiac events (new MI, rehospitalization for PCI in coronary artery territories that were treated, death, or rehospitalization for acute coronary syndrome and for congestive heart failure).
(Incidence rate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in Fixed Perfusion Defect(s)Via SPECT</measure>
    <time_frame>Measured at Baseline and Month 6</time_frame>
    <description>Fixed total defect is the stress total defect minus the reversible component.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Chronic Ischemic Heart Disease</condition>
  <condition>Left Ventricular Dysfunction</condition>
  <condition>Angina</condition>
  <condition>Ischemic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Placebo Injections</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo injections.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Stem Cell Injections</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive active stem cell injections.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adult stem cells</intervention_name>
    <description>Single procedure of intramyocardial electromechanical-guided injection of approximately 100 million bone marrow mononucleated cells (BM-MNCs), administered in 15 different injection sites</description>
    <arm_group_label>Active Stem Cell Injections</arm_group_label>
    <other_name>Adult autologous stem cells</other_name>
    <other_name>Bone marrow mononucleated cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single procedure of intramyocardial electromechanical-guided needle insertions and injection of 5% human serum albumin and saline in 15 different injection sites</description>
    <arm_group_label>Placebo Injections</arm_group_label>
    <other_name>Human serum albumin</other_name>
    <other_name>HSA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients &gt;18 years of age with significant coronary heart disease not amenable to
             revascularization.

          -  Left ventricular dysfunction (LVEF) less than or equal to 45%, measured by
             echocardiogram; limiting angina (Class II to IV); and/or congestive heart failure
             (CHF), NYHA class II to III

          -  Receiving maximal medical therapy, defined as a medical regimen that includes the
             maximal tolerated dose of at least two antiangina medications, such as beta-blockers,
             nitrates, or calcium-channel blockers

          -  Presence of a defect, as identified by single photon emission computed tomography
             (SPECT) isotope protocol, or viability, as identified by NOGA electromechanical
             cardiac mapping system

          -  Coronary artery disease not well suited to any other type of revascularization
             procedure in the target region of the ventricle, as determined by a cardiovascular
             surgeon and interventional cardiologist who are not investigators in the trial

          -  Hemodynamic stability, as defined by systolic blood pressure of at least 80 mm Hg
             without intravenous pressors or support devices

          -  Females of childbearing potential must be willing to use two forms of birth control
             for the duration of the study

        Exclusion Criteria:

          -  Atrial fibrillation or flutter without a pacemaker that guarantees a stable heart rate

          -  Unstable angina

          -  Left ventricular (LV) thrombus, as documented by echocardiography or LV angiography

          -  A vascular anatomy that precludes cardiac catheterization

          -  Severe valvular disease or mechanical aortic valve that precludes safe entry of the
             catheter into the left ventricle

          -  Pregnant or lactating

          -  Platelet count less than 100,000 per mm3

          -  White blood cell count less than 2,000 per mm3

          -  Revascularization within 30 days of consent

          -  Transient ischemic attack or stroke within 60 days of study consent

          -  Implantable cardioverter-defibrillator shock within 30 days of baseline consent, and
             within 30 days of randomization

          -  Presence of ventricular tachycardia lasting 30 seconds or more on 24-hour Holter
             monitor or electrocardiogram (ECG) performed during screening period

          -  Bleeding diathesis, defined as an international normalized ratio of at least 2.0 in
             the absence of warfarin therapy

          -  A history of malignancy in the last 5 years excluding basal cell carcinoma, that has
             been surgically removed, with proof of surgical clean margins

          -  Has a known history of HIV, has active hepatitis B or active hepatitis C

          -  Any condition requiring immunosuppressive medication

          -  High-risk acute coronary syndrome (ACS) or a myocardial infarction in the month prior
             to consent

          -  A left ventricular wall thickness of &lt;8 mm (by echocardiogram) of the infero-lateral
             wall at the target site for cell injection.

          -  Inability to walk on a treadmill, except for class IV angina patients, who will be
             evaluated separately

          -  Enrolled in an investigational device or drug study within the previous 30 days

          -  Hepatic dysfunction, as defined as aspartate aminotransferase (AST) or alanine
             aminotransferase (ALT) more than 1.5 times the upper limit of normal range prior to
             study entry

          -  Chronic renal insufficiency, defined as a serum creatinine level greater than 2.5
             mg/dL or requiring dialysis

          -  Any other condition that in the judgment of the investigator would be a
             contraindication to enrollment or follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Simari, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cardiovascular Cell Therapy Research Network</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida-Department of Medicine</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute Foundation</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Heart Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cctrn.org</url>
    <description>Click here for more information on the Cardiovascular Cell Therapy Research Network</description>
  </link>
  <link>
    <url>http://www.nhlbi.nih.gov</url>
    <description>Click here for more information on the National Heart, Lung, and Blood Institute</description>
  </link>
  <link>
    <url>http://vascularbiomed.iu.edu</url>
    <description>Click here for more information on the Indiana Center for Vascular Biology and Medicine</description>
  </link>
  <reference>
    <citation>Gee AP, Richman S, Durett A, McKenna D, Traverse J, Henry T, Fisk D, Pepine C, Bloom J, Willerson J, Prater K, Zhao D, Koç JR, Ellis S, Taylor D, Cogle C, Moyé L, Simari R, Skarlatos S. Multicenter cell processing for cardiovascular regenerative medicine applications: the Cardiovascular Cell Therapy Research Network (CCTRN) experience. Cytotherapy. 2010 Sep;12(5):684-91. doi: 10.3109/14653249.2010.487900.</citation>
    <PMID>20524773</PMID>
  </reference>
  <reference>
    <citation>Willerson JT, Perin EC, Ellis SG, Pepine CJ, Henry TD, Zhao DX, Lai D, Penn MS, Byrne BJ, Silva G, Gee A, Traverse JH, Hatzopoulos AK, Forder JR, Martin D, Kronenberg M, Taylor DA, Cogle CR, Baraniuk S, Westbrook L, Sayre SL, Vojvodic RW, Gordon DJ, Skarlatos SI, Moyé LA, Simari RD; Cardiovascular Cell Therapy Research Network (CCTRN). Intramyocardial injection of autologous bone marrow mononuclear cells for patients with chronic ischemic heart disease and left ventricular dysfunction (First Mononuclear Cells injected in the US [FOCUS]): Rationale and design. Am Heart J. 2010 Aug;160(2):215-23. doi: 10.1016/j.ahj.2010.03.029.</citation>
    <PMID>20691824</PMID>
  </reference>
  <reference>
    <citation>Zierold C, Carlson MA, Obodo UC, Wise E, Piazza VA, Meeks MW, Vojvodic RW, Baraniuk S, Henry TD, Gee AP, Ellis SG, Moyé LA, Pepine CJ, Cogle CR, Taylor DA. Developing mechanistic insights into cardiovascular cell therapy: Cardiovascular Cell Therapy Research Network Biorepository Core Laboratory rationale. Am Heart J. 2011 Dec;162(6):973-80. doi: 10.1016/j.ahj.2011.05.024.</citation>
    <PMID>22137069</PMID>
  </reference>
  <results_reference>
    <citation>Perin EC, Willerson JT, Pepine CJ, Henry TD, Ellis SG, Zhao DX, Silva GV, Lai D, Thomas JD, Kronenberg MW, Martin AD, Anderson RD, Traverse JH, Penn MS, Anwaruddin S, Hatzopoulos AK, Gee AP, Taylor DA, Cogle CR, Smith D, Westbrook L, Chen J, Handberg E, Olson RE, Geither C, Bowman S, Francescon J, Baraniuk S, Piller LB, Simpson LM, Loghin C, Aguilar D, Richman S, Zierold C, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moyé LA, Simari RD; Cardiovascular Cell Therapy Research Network (CCTRN). Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA. 2012 Apr 25;307(16):1717-26. doi: 10.1001/jama.2012.418. Epub 2012 Mar 24. Erratum in: JAMA. 2015 Jul 7;314(1):86.</citation>
    <PMID>22447880</PMID>
  </results_reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2009</study_first_submitted>
  <study_first_submitted_qc>January 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2009</study_first_posted>
  <results_first_submitted>August 30, 2012</results_first_submitted>
  <results_first_submitted_qc>February 22, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 4, 2013</results_first_posted>
  <last_update_submitted>June 2, 2015</last_update_submitted>
  <last_update_submitted_qc>June 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Dr Lemuel A Moye III</investigator_full_name>
    <investigator_title>Professor - School of Public Health</investigator_title>
  </responsible_party>
  <keyword>Congestive Heart Failure</keyword>
  <keyword>Regional Wall Motion</keyword>
  <keyword>Perfusion Defects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Ventricular Dysfunction</mesh_term>
    <mesh_term>Ventricular Dysfunction, Left</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment took place at five Network centers and their associated satellite facilities between April 29, 2009 and April 18, 2011. The main centers are located in Ohio, Texas, Florida, Minnesota, and Tennessee. Study brochures, patient informational DVDs, and clinical trials.gov were among the tools used for recruitment.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo Injections</title>
          <description>Participants will receive placebo injections.</description>
        </group>
        <group group_id="P2">
          <title>Active Stem Cell Injections</title>
          <description>Participants will receive active stem cell injections.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Injections</title>
          <description>Participants will receive placebo injections.</description>
        </group>
        <group group_id="B2">
          <title>Active Stem Cell Injections</title>
          <description>Participants will receive active stem cell injections.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="61"/>
            <count group_id="B3" value="92"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.32" spread="8.25"/>
                    <measurement group_id="B2" value="63.95" spread="10.90"/>
                    <measurement group_id="B3" value="63.4" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Maximal Oxygen Consumption (VO2max)</title>
        <description>The VO2(max) is assessed using the Naughton treadmill protocol.</description>
        <time_frame>Measured at Baseline and Month 6</time_frame>
        <population>Only participants with both baseline and 6 month VO2max data available are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Injections</title>
            <description>Participants received placebo injections.</description>
          </group>
          <group group_id="O2">
            <title>Active Stem Cell Injections</title>
            <description>Participants received active stem cell injections.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Maximal Oxygen Consumption (VO2max)</title>
          <description>The VO2(max) is assessed using the Naughton treadmill protocol.</description>
          <population>Only participants with both baseline and 6 month VO2max data available are included.</population>
          <units>mL/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="3.2"/>
                    <measurement group_id="O2" value="0.4" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Compare the change in the cell group to the change in the placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.169</p_value>
            <p_value_desc>No adjustment for multiple comparisons</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.42</ci_lower_limit>
            <ci_upper_limit>2.34</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Left Ventricular End Systolic Volume (LVESV)as Assessed Via Echo</title>
        <description>Echocardiographic measurements were performed by an echocardiographic core laboratory. LVESVs were calculated by the modified biplane Simpson method, using myocardial contrast to enhance endocardial definition. To account for patient body surface area, LVESV indices are reported.</description>
        <time_frame>Measured at Baseline and Month 6</time_frame>
        <population>Only participants with both baseline and six month LVESV data available are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Injections</title>
            <description>Participants received placebo injections.</description>
          </group>
          <group group_id="O2">
            <title>Active Stem Cell Injections</title>
            <description>Participants received active stem cell injections.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular End Systolic Volume (LVESV)as Assessed Via Echo</title>
          <description>Echocardiographic measurements were performed by an echocardiographic core laboratory. LVESVs were calculated by the modified biplane Simpson method, using myocardial contrast to enhance endocardial definition. To account for patient body surface area, LVESV indices are reported.</description>
          <population>Only participants with both baseline and six month LVESV data available are included.</population>
          <units>mL/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="10.8"/>
                    <measurement group_id="O2" value="-0.9" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in the difference of end systolic volume over time.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.856</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>23.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.05</ci_lower_limit>
            <ci_upper_limit>12.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Reversible Defect Size</title>
        <description>Adenosine myocardial perfusion (SPECT) tests were collected at baseline and 6 months to identify change in ischemic (reversible) defects. SPECT imaging was performed at rest and after adenosine infusion over 4 minutes. To enhance the detection of viability on resting images, sublingual nitroglycerin was administered 15 minutes before injecting technetium Tc 99m sestamibi for the resting image.</description>
        <time_frame>Measured at Baseline and Month 6</time_frame>
        <population>Only participants with both baseline and six month reversible defect data available are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Injections</title>
            <description>Participants received placebo injections.</description>
          </group>
          <group group_id="O2">
            <title>Active Stem Cell Injections</title>
            <description>Participants received active stem cell injections.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Reversible Defect Size</title>
          <description>Adenosine myocardial perfusion (SPECT) tests were collected at baseline and 6 months to identify change in ischemic (reversible) defects. SPECT imaging was performed at rest and after adenosine infusion over 4 minutes. To enhance the detection of viability on resting images, sublingual nitroglycerin was administered 15 minutes before injecting technetium Tc 99m sestamibi for the resting image.</description>
          <population>Only participants with both baseline and six month reversible defect data available are included.</population>
          <units>percentage of reversible defect</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="18.2"/>
                    <measurement group_id="O2" value="-3.9" spread="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in percent of the defect that is reversible</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.835</p_value>
            <p_value_desc>Is the change in percent reversible defect the same between the two groups</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>22.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.5</ci_lower_limit>
            <ci_upper_limit>10.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Regional Wall Motion by MRI (in Eligible Patients)</title>
        <description>Regional wall motion as measured by cardiac MRI (in patients who are not contraindicated)</description>
        <time_frame>Measured at Baseline and Month 6</time_frame>
        <population>The small number of patients without contraindications for MRI (n=17) precluded performing informative analysis on the MRI data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Injections</title>
            <description>Participants received placebo injections.</description>
          </group>
          <group group_id="O2">
            <title>Active Stem Cell Injections</title>
            <description>Participants received active stem cell injections.</description>
          </group>
        </group_list>
        <measure>
          <title>Regional Wall Motion by MRI (in Eligible Patients)</title>
          <description>Regional wall motion as measured by cardiac MRI (in patients who are not contraindicated)</description>
          <population>The small number of patients without contraindications for MRI (n=17) precluded performing informative analysis on the MRI data.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Regional Blood Flow Improvement by MRI (in Eligible Patients)</title>
        <description>Regional blood flow improvement as measured by cardiac MRI (in patients who are not contraindicated)</description>
        <time_frame>Measured at Baseline and Month 6</time_frame>
        <population>The small number of patients without contraindications for MRI (n=17) precluded performing informative analysis on the MRI data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Injections</title>
            <description>Participants received placebo injections.</description>
          </group>
          <group group_id="O2">
            <title>Active Stem Cell Injections</title>
            <description>Participants received active stem cell injections.</description>
          </group>
        </group_list>
        <measure>
          <title>Regional Blood Flow Improvement by MRI (in Eligible Patients)</title>
          <description>Regional blood flow improvement as measured by cardiac MRI (in patients who are not contraindicated)</description>
          <population>The small number of patients without contraindications for MRI (n=17) precluded performing informative analysis on the MRI data.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Regional Wall Motion by Echocardiography</title>
        <description>Movement of the left ventricular wall measured in mm from baseline to six months.</description>
        <time_frame>Measured at Baseline and Month 6</time_frame>
        <population>Only participants with both baseline and six month wall motion data available are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Injections</title>
            <description>Participants received placebo injections.</description>
          </group>
          <group group_id="O2">
            <title>Active Stem Cell Injections</title>
            <description>Participants received active stem cell injections.</description>
          </group>
        </group_list>
        <measure>
          <title>Regional Wall Motion by Echocardiography</title>
          <description>Movement of the left ventricular wall measured in mm from baseline to six months.</description>
          <population>Only participants with both baseline and six month wall motion data available are included.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.4"/>
                    <measurement group_id="O2" value="0" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference in the change between the two groups</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.471</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.30</ci_lower_limit>
            <ci_upper_limit>0.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Improvement in CCS Classification (Angina Pectoris)</title>
        <description>Clinical improvement in Canadian Cardiovascular Society (CCS) functional classification of angina pectoris. The CCS scale ranges from Class I (best)&quot;able to conduct ordinary daily activity without causing angina&quot; to Class IV (worst) &quot;Inability to perform any physical activity without discomfort; anginal symptoms may be present at rest.&quot; Patients receive a rating of 1-4 for their anginal symptoms. Results reflect the mean change in the total score over time.</description>
        <time_frame>Measured at Baseline and Month 6</time_frame>
        <population>Only participants with both baseline and six month CCS data available are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Injections</title>
            <description>Participants received placebo injections.</description>
          </group>
          <group group_id="O2">
            <title>Active Stem Cell Injections</title>
            <description>Participants received active stem cell injections.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Improvement in CCS Classification (Angina Pectoris)</title>
          <description>Clinical improvement in Canadian Cardiovascular Society (CCS) functional classification of angina pectoris. The CCS scale ranges from Class I (best)&quot;able to conduct ordinary daily activity without causing angina&quot; to Class IV (worst) &quot;Inability to perform any physical activity without discomfort; anginal symptoms may be present at rest.&quot; Patients receive a rating of 1-4 for their anginal symptoms. Results reflect the mean change in the total score over time.</description>
          <population>Only participants with both baseline and six month CCS data available are included.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.7"/>
                    <measurement group_id="O2" value="-0.5" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in average improvement in Canadian Class Score over time between the two groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.227</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.25</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.784</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.66</ci_lower_limit>
            <ci_upper_limit>0.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Improvement in NYHA Classification</title>
        <description>Clinical improvement in New York Heart Association (NYHA) classification. The NYHA scale ranges from 1 (best)&quot;Mild- no limitation of physical activity due to heart failure&quot; to 4 (worst) &quot;Severe-Unable to carry out any physical activity without discomfort due to heart failure&quot;. Patients receive a rating of 1-4 for their heart failure symptoms. Results reflect the mean change in the total score over time.</description>
        <time_frame>Measured at Baseline and Month 6</time_frame>
        <population>Only participants with both baseline and six month NYHA class data available are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Injections</title>
            <description>Participants received placebo injections.</description>
          </group>
          <group group_id="O2">
            <title>Active Stem Cell Injections</title>
            <description>Participants received active stem cell injections.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Improvement in NYHA Classification</title>
          <description>Clinical improvement in New York Heart Association (NYHA) classification. The NYHA scale ranges from 1 (best)&quot;Mild- no limitation of physical activity due to heart failure&quot; to 4 (worst) &quot;Severe-Unable to carry out any physical activity without discomfort due to heart failure&quot;. Patients receive a rating of 1-4 for their heart failure symptoms. Results reflect the mean change in the total score over time.</description>
          <population>Only participants with both baseline and six month NYHA class data available are included.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.7"/>
                    <measurement group_id="O2" value="-0.3" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference in the change in NYHA score between the two groups</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.361</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.176</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.845</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.56</ci_lower_limit>
            <ci_upper_limit>0.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Decrease in Anti-anginal Medication</title>
        <description>Number of participants with a decrease in anti-anginal medication (nitrates needed weekly)</description>
        <time_frame>Measured at Baseline and Month 6</time_frame>
        <population>Only participants with both baseline and six month anti-anginal medication data available are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Injections</title>
            <description>Participants received placebo injections.</description>
          </group>
          <group group_id="O2">
            <title>Active Stem Cell Injections</title>
            <description>Participants received active stem cell injections.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Decrease in Anti-anginal Medication</title>
          <description>Number of participants with a decrease in anti-anginal medication (nitrates needed weekly)</description>
          <population>Only participants with both baseline and six month anti-anginal medication data available are included.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference in the change in anti-anginal meds across groups</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.28</p_value>
            <method>Chi-squared</method>
            <param_type>Difference in the proportion of particip</param_type>
            <param_value>0.04</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.045</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.01</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exercise Time and Level</title>
        <description>Exercise time and level as assessed via six minute walk test. (change in number of feet walked)</description>
        <time_frame>Measured at Baseline and Month 6</time_frame>
        <population>Only participants with both baseline and six month 6 minute walk data available are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Injections</title>
            <description>Participants received placebo injections.</description>
          </group>
          <group group_id="O2">
            <title>Active Stem Cell Injections</title>
            <description>Participants received active stem cell injections.</description>
          </group>
        </group_list>
        <measure>
          <title>Exercise Time and Level</title>
          <description>Exercise time and level as assessed via six minute walk test. (change in number of feet walked)</description>
          <population>Only participants with both baseline and six month 6 minute walk data available are included.</population>
          <units>feet</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" spread="415"/>
                    <measurement group_id="O2" value="184" spread="407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in six minute walk distance</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.302</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>104</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>409</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-95</ci_lower_limit>
            <ci_upper_limit>303</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum BNP Levels in Patients With CHF</title>
        <description>Serum b-type natriuretic peptide (BNP) levels in patients with congestive heart failure (CHF). A minority number of patients had pro-BNP collected versus regular BNP; these numbers are reported in the analysis population description.</description>
        <time_frame>Measured at Baseline and Month 6</time_frame>
        <population>Only participants with both baseline and six month BNP data available are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Injections</title>
            <description>Participants received placebo injections.</description>
          </group>
          <group group_id="O2">
            <title>Active Stem Cell Injections</title>
            <description>Participants received active stem cell injections.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum BNP Levels in Patients With CHF</title>
          <description>Serum b-type natriuretic peptide (BNP) levels in patients with congestive heart failure (CHF). A minority number of patients had pro-BNP collected versus regular BNP; these numbers are reported in the analysis population description.</description>
          <population>Only participants with both baseline and six month BNP data available are included.</population>
          <units>IUs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BNP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63" spread="249"/>
                    <measurement group_id="O2" value="28" spread="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pro-BNP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="234" spread="1636"/>
                    <measurement group_id="O2" value="497" spread="1637"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference in the change in BNP(reg) between cell and placebo group</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.55</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-34.7</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>176</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-150</ci_lower_limit>
            <ci_upper_limit>80</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LV Diastolic Dimension</title>
        <description>Left ventricular (LV) diastolic dimension as assessed by contrast echocardiography</description>
        <time_frame>Measured at Baseline and Month 6</time_frame>
        <population>Only participants with both baseline and six month LV diastolic data available are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Injections</title>
            <description>Participants received placebo injections.</description>
          </group>
          <group group_id="O2">
            <title>Active Stem Cell Injections</title>
            <description>Participants received active stem cell injections.</description>
          </group>
        </group_list>
        <measure>
          <title>LV Diastolic Dimension</title>
          <description>Left ventricular (LV) diastolic dimension as assessed by contrast echocardiography</description>
          <population>Only participants with both baseline and six month LV diastolic data available are included.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.5" spread="34"/>
                    <measurement group_id="O2" value="0.9" spread="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in the difference of end diastolic volume between the two groups over time.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.198</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>9.5</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>31.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.03</ci_lower_limit>
            <ci_upper_limit>23.93</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of a Major Adverse Cardiac Event</title>
        <description>Incidence of major adverse cardiac events (new MI, rehospitalization for PCI in coronary artery territories that were treated, death, or rehospitalization for acute coronary syndrome and for congestive heart failure).
(Incidence rate)</description>
        <time_frame>Measured at Baseline and Month 6</time_frame>
        <population>Incidence of major adverse cardiac events between baseline and 6 months. (Incidence rate)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Injections</title>
            <description>Participants received placebo injections.</description>
          </group>
          <group group_id="O2">
            <title>Active Stem Cell Injections</title>
            <description>Participants received active stem cell injections.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of a Major Adverse Cardiac Event</title>
          <description>Incidence of major adverse cardiac events (new MI, rehospitalization for PCI in coronary artery territories that were treated, death, or rehospitalization for acute coronary syndrome and for congestive heart failure).
(Incidence rate)</description>
          <population>Incidence of major adverse cardiac events between baseline and 6 months. (Incidence rate)</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The difference in the incidence of major adverse cardiac events between the two groups over time. (Incidence rate)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.47</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference in the incidence rates</param_type>
            <param_value>-0.047</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.044</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.133</ci_lower_limit>
            <ci_upper_limit>0.039</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reduction in Fixed Perfusion Defect(s)Via SPECT</title>
        <description>Fixed total defect is the stress total defect minus the reversible component.</description>
        <time_frame>Measured at Baseline and Month 6</time_frame>
        <population>Only participants with both baseline and six month fixed defect data available are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Injections</title>
            <description>Participants received placebo injections.</description>
          </group>
          <group group_id="O2">
            <title>Active Stem Cell Injections</title>
            <description>Participants received active stem cell injections.</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction in Fixed Perfusion Defect(s)Via SPECT</title>
          <description>Fixed total defect is the stress total defect minus the reversible component.</description>
          <population>Only participants with both baseline and six month fixed defect data available are included.</population>
          <units>percentage of defect that is fixed</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="7.7"/>
                    <measurement group_id="O2" value="1.2" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference in the change between the two groups</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.78</ci_lower_limit>
            <ci_upper_limit>3.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Events reported are from Randomization Date to the 6 month endpoint data collection window (i.e. 210 days post intervention)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo Injections</title>
          <description>Participants received placebo injections.</description>
        </group>
        <group group_id="E2">
          <title>Active Stem Cell Injections</title>
          <description>Participants received active stem cell injections.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="7" subjects_affected="3" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Heart Failure</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <description>Tachycardia not requiring hospitalization or a change to current therapy</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Change in BNP levels</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Sample size was small and required large improvements in order to show significant treatment effects. SPECT often underestimates reversibility and viability in those with multivessel disease. Presence of cardiac devices limited MRI evaluation.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Lemuel Moye, MD, PhD</name_or_title>
      <organization>UT-Houston School of Public Health</organization>
      <phone>713-500-9518</phone>
      <email>Lemmoye@msn.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

